NARK Pharmaceuticals

NARK Pharmaceuticals is a specialty pharmaceutical company focused on the development of intranasal delivery systems for rescue medications and emergency treatments. The company is best known for its foundational intellectual property related to the intranasal delivery of naloxone, which served as the basis for the first FDA-approved nasal spray for reversing opioid overdoses. NARK Pharmaceuticals licensed its core technology to Opiant Pharmaceuticals (formerly Lightlake Therapeutics), which subsequently partnered with Adapt Pharma and Emergent BioSolutions to commercialize the product under the brand name Narcan. The company's business model centers on the research and development of non-invasive, rapid-acting delivery methods for treatments where bioavailability and speed of onset are critical. Their expertise lies in optimizing the absorption of small molecules through the nasal mucosa to replace or augment traditional injectable routes.